|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
N-Methylhistamine, Random, Urine
Test Code39604
Includes
Creatinine
Preferred Specimen
Urine collected in Sterile Cup
Patient Preparation
Patient must not be taking monoamine oxidase inhibitors (MAOIs) or aminoguanidine as these medications increase N-methylhistamine (NMH) levels.
Minimum Volume
3 mL
Instructions
1. Collect a random urine specimen within a few hours of symptom onset.
2. No preservative
Advisory Information: Patients with chronic mast cell activation often have chronically elevated N-methylhistamine (NMH) levels and will sometimes have intermittent NHM elevations. In these cases, a 24-hour collection is preferred. See NMH24/N-Methlyhistamine, 24 Hour, Urine.
Note: Random urine collections are preferred for patients with episodic symptoms, for example in the context of allergic reactions, brought on by specific environmental factors. See NMHR / N-Methylhistamine, Random, Urine.
2. No preservative
Advisory Information: Patients with chronic mast cell activation often have chronically elevated N-methylhistamine (NMH) levels and will sometimes have intermittent NHM elevations. In these cases, a 24-hour collection is preferred. See NMH24/N-Methlyhistamine, 24 Hour, Urine.
Note: Random urine collections are preferred for patients with episodic symptoms, for example in the context of allergic reactions, brought on by specific environmental factors. See NMHR / N-Methylhistamine, Random, Urine.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 14 days
Refrigerated: 28 days
Frozen: 28 days
Refrigerated: 28 days
Frozen: 28 days
Methodology
Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS) • Enzymatic Colorimetric Assay
Setup Schedule
A.M. Sets up 2 days a week.
Report Available
Reports in 4 to 9 days.
Reference Range
N-Methylhistamine, Random, Urine
| 0-5 years | 120-510 mcg/g Cr |
| 6-16 years | 70-330 mcg/g Cr |
| >16 years | 30-200 mcg/g Cr |
| Creatinine, Random, Urine | See Laboratory Report |
Clinical Significance
Screening for and monitoring of mastocytosis and disorders of systemic mast-cell activation, such as anaphylaxis and other forms of severe systemic allergic reactions using random urine specimens.
Monitoring therapeutic progress in conditions that are associated with secondary, localized, low-grade persistent, mast-cell proliferation and activation such as interstitial cystitis.
Monitoring therapeutic progress in conditions that are associated with secondary, localized, low-grade persistent, mast-cell proliferation and activation such as interstitial cystitis.
